# Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study

> **NCT05612594** · PHASE4 · RECRUITING · sponsor: **Yale University** · enrollment: 164 (estimated)

## Conditions studied

- Sleep Apnea

## Interventions

- **DRUG:** Bexagliflozin 20 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05612594
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-27
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2025-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05612594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05612594, "Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05612594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*